Gatifloxacin
Zymar · TEQUIN · CG5501 · S)-AHPC · Gatiquin · PD135432 · PD 135432 · PD-135432)
식별자 및 물리적 특성
| CAS No. | 112811-59-3 |
|---|---|
| 분자식 | C19H22FN3O4 |
| 평균 분자량 | 375.4 g/mol |
| 단동위원소 질량 | 375.1594344 g/mol |
| SMILES | COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12 |
| InChIKey | XUBOMFCQGDBHNK-UHFFFAOYSA-N |
| PubChem CID | 5379 |
| ChEMBL | CHEMBL31 |
| ChEBI | CHEBI:5280 |
| EC No. | 664-293-2 |
| DTXSID | DTXSID5045704 |
화학 및 물리적 성질
| XLogP | -0.7 |
|---|---|
| 극성 표면적 | 82.1 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 8 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 27 |
| 형식 전하 | 0 |
| 복잡도 | 653 |
| 의약품 | Pharmaceuticals -> AntibioticsPharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use |
| LogP(분배 계수) | 2.6 |
| 용해도 | 6.31e-01 g/L클로로포름(약간 용해됨, 가열), 메탄올(약간 용해됨, 가열) |
| Human Drugs | Breast FeedingLactationMilk, HumanAnti-Infective AgentsAntibacterial AgentsQuinolonesFluoroquinolonesFDA approved drugs -> Active ingredient |
| 녹는점 | 182-185 °C182 - 185 °C162°C |
| Physical Description | Solid |
| Dissociation Constants | 8.7469.4 |
| Collision Cross Section | 189.5 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]189.03 Ų [M+H]+ [CCS Type: TW |
| 끓는 점 | 607.8±55.0 °C(Predicted) |
| 밀도 | 1.386±0.06 g/cm3(Predicted) |
| 저장 조건 | Sealed in dry,2-8°C |
| pKa(산도 계수) | 6.43±0.50(Predicted) |
| 물리적 상태 | 백색 내지 황색 결정성 분말. |
| 색상 | 흰색에서 황백색까지 |
| 주요 응용 | 의약품(소분자) |
| InChI | InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26) |
| InChIKey | XUBOMFCQGDBHNK-UHFFFAOYSA-N |
| SMILES | N1(C2CC2)C2=C(C=C(F)C(N3CCNC(C)C3)=C2OC)C(=O)C(C(O)=O)=C1 |
화학적 성질
White to light yellow powder
안전 및 규제
| GHS 분류 | WarningH302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (97.5%) |
| Treatment | In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained. (L1712) |
| 건강 영향 | Antibiotic resistance |
| 노출 경로 | Ophthalmic. Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96% |
| 독성 요약 | The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. |
| Signs and Symptoms | The most common side effects from antibiotics are diarrhea, nausea, vomiting. Fungal infections of the mouth, digestive tract and vagina can also occur with antibiotics |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 수질 위해 등급(WGK) | WGK 1 |
| 관세 코드 | 29335990 |
| 위험 문구(R) | 20/21/22 |
| 위험 표시 | Xn |
| 안전 문구(S) | 36/37 |
| 위험 등급 | Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 Oral |
용도
개요
Gatifloxacin belongs to a class of drugs known as quinolone antibiotics and is used to treat acute sinus, lung, or urinary tract infections and sexually transmitted bacterial infection.This drug may be taken orally, in tablet form, or by injection.Common side effects associated with gatifloxacin include nausea, vaginitis(irritation or inflammation of the vagina)，diarrhea, headache, dizziness, and irregular heart beats. In general, gatifloxacin is used in people who are unresponsive to other AOM therapies.In one study, gatifloxacin was compared with amoxicillin/clavulanate in the treatment of recurrent otitis media (OM) and AOM in treatment failures in children.Three hundred fifty-four infants and children with recurrent OM or AOM failure received gatifloxacin or amoxicillin/clavulanate.Results showed that both drugs were well tolerated; the most common side effect was diarrhea.Researchers concluded that treatment with gatifloxacin once daily was as effective as amoxicillin/clavulanate twice daily.In other medical literature, gatifloxacin has been noted as a third-line treatment option in AOM.